Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.
The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.
MUNDKUR CHRISTINE reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corp director Christine Mundkur reported a new equity award and clarified prior holdings. She received a grant of 82,781 restricted stock units, each representing a contingent right to receive one share of MannKind common stock.
The restricted stock units vested on May 20, 2026, but the underlying shares will not be delivered until she separates from service on MannKind’s board of directors. Following the reported activity, she directly holds 27,675 shares of MannKind common stock. A footnote states that 226,818 shares representing deferred restricted stock units were inadvertently included in earlier reported common stock holdings.
Kay Sabrina reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corporation director Sabrina Kay reported a compensation-related stock award rather than an open-market trade. On May 20, 2026, she received a grant of 82,781 restricted stock units (RSUs), each representing a contingent right to one share of MannKind common stock. The RSU grant is shown with a price of $0.0000 per unit, reflecting that it is an award, not a purchase. The filing also shows she holds 107,033 shares of common stock directly after the reported transactions and 82,781 RSUs outstanding. A footnote explains that 158,567 shares representing deferred restricted stock units had been inadvertently included in prior common-stock holdings and are now correctly reflected as deferred RSUs.
MannKind Corporation reported results from its 2026 Annual Meeting of Stockholders held on May 20, 2026. Stockholders elected nine directors, each receiving over 140 million shares voted in favor, with sizable broker non-votes recorded on the election items.
Stockholders approved, on an advisory basis, the compensation of MannKind’s named executive officers, with 137,332,418 shares voted for, 16,295,138 against, 1,303,497 abstaining, and 78,531,407 broker non-votes. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for 2026, with 221,079,329 shares for, 8,759,982 against, and 3,623,149 abstaining.
MNKD amendment (Form 144/A) reports a proposed sale of Common securities related to Restricted Stock Units with transaction dates listed as 05/10/2026 and 05/12/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker. The filing amends prior information and records broker and security details for a resale filing.
MANNKIND CORP Chief People & Workplace Officer Stuart A. Tross reported a routine tax-related share disposition. On the vesting of restricted stock units originally granted on May 10, 2022, 8,073 shares of common stock were withheld to cover tax withholding obligations at a value of $3.52 per share. After this non-market transaction, Tross directly holds 992,224 shares of MANNKIND CORP common stock.
MannKind Corp director Steven B. Binder reported an open-market sale of 16,940 shares of common stock at a weighted average price of $3.29 per share on May 12, 2026, executed under a Rule 10B5-1 trading plan established on December 2, 2025.
Binder also had 5,560 shares withheld on May 11, 2026 to cover tax obligations arising from the vesting of restricted stock units originally granted on May 10, 2022. Following these transactions, he directly holds 808,008 MannKind shares.
MANNKIND CORP Chief Executive Officer Michael Castagna reported a routine share withholding related to taxes on vested equity. On May 11, 34,957 shares of common stock were withheld at $3.52 per share to satisfy tax withholding obligations from Restricted Stock Units originally granted on May 10, 2022.
These shares were not sold in the open market but used to cover taxes due at vesting. After this transaction, Castagna directly holds 2,442,310 shares of MannKind common stock, which includes 1,356 shares acquired under the company’s Employee Stock Purchase Plan on December 31, 2025.
MannKind Corp executive David Thomson, EVP, General Counsel & Secretary, reported recent transactions in the company’s common stock. He completed an open-market sale of 3,033 shares at a weighted average price of $3.29 per share, executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on August 27, 2025. Separately, 12,387 shares were withheld to cover tax obligations tied to the vesting of restricted stock units that were originally granted on May 10, 2022, which is a non-market, tax-related disposition. After these transactions, Thomson directly holds 826,299 shares of MannKind common stock.